For estrogen-receptor positive tumors, adjuvant tamoxifen reduces contralateral breast cancer risks by as much as 40% [10] - which for long-term survivors represents a risk reduction from about 16% to 10%, still a disturbingly high risk. This evidence concerns the gene ESR1 and breast carcinoma.